Related Experiment Videos
Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy
C Morisco1, L Argenziano, N Tozzi
1Department of Internal Medicine, School of Medicine, Federico II University, Naples, Italy.
Insights
Angiotensin converting enzyme (ACE) inhibitors effectively reduce left ventricular hypertrophy (LVH) in patients with essential hypertension. These drugs promote faster and more complete LVH regression compared to other antihypertensives.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular disease in patients with essential hypertension.
- Antihypertensive therapy can lead to LVH regression, but the effectiveness varies by drug class.
- Angiotensin converting enzyme (ACE) inhibitors demonstrate a notable capacity for reversing LVH.
Purpose of the Study:
- To investigate the mechanisms by which ACE inhibitors induce superior regression of LVH compared to other antihypertensive agents.
- To explore the role of arterial compliance and cardiopulmonary receptor control in ACE inhibitor-mediated LVH reversal.
Main Methods:
- The study reviews existing literature on antihypertensive therapies and their effects on LVH.
- It analyzes the impact of ACE inhibitors on arterial compliance and left ventricular end-systolic stress.
- The potential influence of ACE inhibitors on cardiopulmonary receptor control of circulation is examined.
Main Results:
- ACE inhibitors appear to improve large artery compliance, a key factor in LVH development.
- Reduced arterial compliance in hypertension leads to increased left ventricular end-systolic stress, contributing to LVH.
- ACE inhibitors may also modulate cardiopulmonary receptor control, counteracting neural and hormonal factors in LVH maintenance.
Conclusions:
- ACE inhibitors offer a distinct advantage in promoting LVH regression in hypertensive patients.
- Improved arterial compliance and interference with cardiopulmonary receptor control are likely mechanisms behind this enhanced effect.
- Further research is warranted to fully elucidate the pathways involved in ACE inhibitor-induced LVH reversal.
Abstract:
It is well known that, in patients with essential hypertension, left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular disease. However, it has been demonstrated that normalisation of arterial pressure, by therapy with antihypertensive drugs, is associated with regression of LVH, although the extent and time-course of this phenomenon depend on the antihypertensive drug used. In particular, angiotensin converting enzyme (ACE) inhibitors seem capable of inducing a faster and more complete reversal of LVH in patients with essential hypertension than other antihypertensive drugs. The mechanisms underlying this property of ACE inhibitors remain unclear, although 2 features of ACE inhibitors may be particularly relevant. The first is their ability to improve large artery compliance, this being a major determinant of LVH. Arterial compliance is reduced in essential hypertension, resulting in increased left ventricular end-systolic stress, which then contributes to the development of LVH. The second possible mechanism by which ACE inhibitors reverse LVH to a greater degree than other antihypertensive drugs may relate to their ability to interfere with the cardiopulmonary receptor control of the circulation. Thus, ACE inhibitors may counteract the neural and hormonal abnormalities that contribute to the maintenance of LVH in hypertensive patients.